Analysis of Gal-3 expression across multiple RNA sequencing public datasets, combined with data from the GEPIA website, revealed significantly elevated RNA expression levels of Gal-3 in various tumor types, including colon cancer, diffuse large B-cell lymphoma, glioma, kidney cancer, liver cancer, pancreatic cancer, rectal adenocarcinoma, thyroid cancer, gastric cancer, and thymoma, compared with normal tissues (Fig. 1A). The gene discussed is LGALS3; the disease is central nervous system cancer.